ClinicalTrials.gg
CompletedNCT03321513DRCR ACUpdated Oct 1, 2026Results posted

DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

A Phase 3 interventional study of intravitreous aflibercept and Bevacizumab + Deferred Aflibercept Group in Diabetic Macular Edema, sponsored by Jaeb Center for Health Research. Completed at 54 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Jaeb Center for Health Research · Phase 3, Interventional, and Treatment

Updated Oct 1, 2026Posted results revised1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing bevacizumab in Macular Edema — 3 open to participants now, 3 under way, 2 of them phase 3. Bevacizumab · Macular Edema.

Enrollment
7th of 46
270 · median 63
Started
2017
with 2 others
Phase 3
17 of 50
1 open now
Registered
44th of 50
by date
Lead sponsor
3 of 50
Jaeb Center for Health Research

Among the 50 studies testing bevacizumab in Macular Edema, this one is the 7th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2017, is one of 17 in phase 3, and was the 44th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

3 of the 50 studies testing bevacizumab in Macular Edema are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing bevacizumab in Macular Edema, or all of them as a file.
02

Study summary

Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes. However, aflibercept was shown to be more effective at improving vision, on average, at 1 year and at 2 years. Due to the large cost difference between the two drugs, many clinicians and patients are choosing to initiate treatment with bevacizumab and then switch to aflibercept depending on the eye's response to bevacizumab treatment. However, there is no scientific evidence that this treatment strategy is as effective at improving vision as initiating treatment with aflibercept. Patients and clinicians do not know if this approach ultimately has deleterious effects on visual acuity. If starting with aflibercept is not better than starting with bevacizumab and switching to aflibercept if needed, the potential cost savings to future patients and the health care system would be substantial. However, if starting with aflibercept is better, then patients, clinicians, and health care providers can make informed decisions for how to best treat patients with DME and at least moderate vision loss.

Study Objectives To compare the efficacy of intravitreous aflibercept with intravitreous bevacizumab + deferred aflibercept if needed in eyes with CI DME and moderate vision loss

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • Diabetic Macular Edema
  • anti-vascular endothelial growth factor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participant-level Criteria Inclusion

To be eligible, the following inclusion criteria must be met:

  1. Age ≥ 18 years • Individuals \<18 years old are not being included because DME is so rare in this age group that the diagnosis of DME may be questionable.
  2. Diagnosis of diabetes mellitus (type 1 or type 2)

    • Any one of the following will be considered to be sufficient evidence that diabetes is present:

    Current regular use of insulin for the treatment of diabetes Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes Documented diabetes by American Diabetes Association and/or World Health Organization criteria

  3. At least one eye meets the study eye criteria listed.
  4. Able and willing to provide .

    Exclusion

    An individual is not eligible if any of the following exclusion criteria are present:

  5. Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.
  6. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).

    • Individuals in poor glycemic control who, within the last four months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next four months should not be enrolled.
  7. Participation in an trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied at the time of study entry.

    • Note: study participants cannot receive another investigational drug while participating in the study.
  8. Known allergy to any component of the study drug or any drug used in the injection prep (including povidone iodine prep).
  9. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110).

    • If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.
  10. Systemic anti-VEGF or pro-VEGF treatment within four months prior to randomization or anticipated use during the study.

    • These drugs cannot be used during the study.
  11. For women of : pregnant or lactating or intending to become pregnant within the next 24 months.

    • Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed.
  12. Individual is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the next two years.

Study Eye Criteria The study participant must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below.

Study participants can have two study eyes only if both eyes are eligible at the time of randomization. For study participants with two eligible eyes, the logistical complexities of the protocol must be considered for each individual prior to randomizing both eyes.

The eligibility criteria for a study eye are as follows:

Inclusion

  1. Best corrected Electronic-Early Treatment Diabetic Retinopathy Study visual acuity letter score \< 69 (i.e., 20/50 or worse) and ≥ 24 (i.e., 20/320 or better) within eight days of randomization.
  2. On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula.
  3. Diabetic macular edema present on optical coherence tomography (OCT) within eight days of randomization

    • Zeiss Cirrus central subfield: ≥ 290µm in women or ≥ 305µm in men
    • Heidelberg Spectralis central subfield: ≥ 305µm in women or ≥ 320µm in men
    • Investigator must verify accuracy of OCT scan by ensuring it is centered and of adequate quality
  4. Media clarity, pupillary dilation, and individual cooperation sufficient for adequate fundus photographs.

    Exclusions

    The following exclusions apply to the study eye only (i.e., they may be present for the nonstudy eye):

  5. Macular edema is considered to be due to a cause other than diabetic macular edema.

    • An eye should not be considered eligible if: (1) the macular edema is considered to be related to ocular surgery such as cataract extraction or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema.
  6. An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).
  7. An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).
  8. Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by three lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).
  9. History of an anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) in the past 12 months or history of any other treatment for DME at any time in the past four months (such as focal/grid macular photocoagulation, intravitreous or peribulbar ).

    • Enrollment will be limited to a maximum of 25% of the planned sample size with any history of anti-VEGF treatment for DME. Once this number of eyes has been enrolled, any history of anti-VEGF treatment for DME will be an exclusion criterion.
  10. History of pan-retinal photocoagulation within four months prior to randomization or anticipated need for pan-retinal photocoagulation in the six months following randomization.
  11. History of anti-VEGF treatment for a disease other than DME in the past 12 months.
  12. History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior four months or anticipated within the next six months following randomization.
  13. History of YAG capsulotomy performed within two months prior to randomization.
  14. Aphakia.
  15. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.
  16. Evidence of uncontrolled glaucoma. • Intraocular pressure must be \<30, with no more than one topical glaucoma medication, and no documented glaucomatous field loss for the eye to be eligible

Note, combination therapies are considered more than one medication

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
270 participants (actual)

Study arms

  • Active comparator
    Aflibercept Group

    2.0 mg intravitreous aflibercept

    Drug: intravitreous aflibercept

  • Experimental
    Bevacizumab + Deferred Aflibercept Group

    1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria

    Drug: intravitreous aflibercept · Drug: Bevacizumab + Deferred Aflibercept Group

Interventions

  • Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema. Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert. Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used. The injection will be performed using sterile technique

    Also known as: Eylea

  • DrugBevacizumab + Deferred Aflibercept Group

    Drug page: Bevacizumab

    Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma. Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc. Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used. The injection will be performed using a sterile technique.

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Mean Change in Visual Acuity

    Area under the curve mean change in the electronic early treatment diabetic retinopathy study visual acuity. Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction. The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up.

    Time frame: 2 years

Secondary outcomes

  1. Change in Visual Acuity From Baseline

    Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.

    Time frame: 2 years

  2. Increase in E-ETDRS Visual Acuity Letter Score

    Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.

    Time frame: 2 years

  3. Decrease in E-ETDRS Visual Acuity Letter Score

    Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.

    Time frame: 2 years

  4. Visual Acuity

    Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.

    Time frame: 2 years

  5. Optical Coherence Tomography Central Subfield Thickness Change From Baseline

    Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score.

    Time frame: 2 years

  6. Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema

    Optical coherence tomography (OCT) central subfield thickness equivalents for measurements obtained on Spectral domain OCT machines were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively on the Cirrus OCT measurement device (Zeiss).

    Time frame: 2 years

  7. Number of Visits

    Time frame: 2 years

  8. Number of Injections

    All study injections were counted, including aflibercept injections received among eyes in the bevacizumab first group.

    Time frame: 2 years

  9. Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria

    Time frame: Baseline to 12 weeks

  10. Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria

    Time frame: Baseline to 24 weeks

  11. Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria

    Time frame: Baseline to 52 weeks

  12. Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria

    Time frame: Baseline to 104 weeks

07

Results

Posted Apr 25, 2024

Participant flow

Participant flow — Overall Study
MilestoneAflibercept- Monotherapy GroupBevacizumab-First Group
Started158154
Completed132128
Not completed2626
Withdrew: Death115
Withdrew: Withdrawal by subject510
Withdrew: Lost to follow-up1011

Outcome measures

PrimaryMean Change in Visual Acuity

Area under the curve mean change in the electronic early treatment diabetic retinopathy study visual acuity. Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction. The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up.

Time frame:
2 years
Reported as:
Mean · Letter Score
Mean Change in Visual Acuity
Letter ScoreAflibercept- Monotherapy GroupBevacizumab-First Group
Overall15 ± 8.514 ± 8.8
Female13.4 ± 7.913.1 ± 9.0
Male16.7 ± 8.814.8 ± 8.6
Black or African American14.2 ± 8.013.5 ± 10
Hispanic or Latino12.2 ± 9.113.0 ± 9.4
White16.8 ± 8.014.8 ± 8.3
SecondaryChange in Visual Acuity From Baseline

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.

Time frame:
2 years
Reported as:
Mean · Letter Score
Change in Visual Acuity From Baseline
Letter ScoreAflibercept- Monotherapy GroupBevacizumab-First Group
Change in Visual Acuity From Baseline14.7 ± 14.515.9 ± 12.4
SecondaryIncrease in E-ETDRS Visual Acuity Letter Score

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.

Time frame:
2 years
Reported as:
Count of units · Eyes
Increase in E-ETDRS Visual Acuity Letter Score
EyesAflibercept- Monotherapy GroupBevacizumab-First Group
15 or more letters7074
10 or more letters10198
SecondaryDecrease in E-ETDRS Visual Acuity Letter Score

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.

Time frame:
2 years
Reported as:
Count of units · Eyes
Decrease in E-ETDRS Visual Acuity Letter Score
EyesAflibercept- Monotherapy GroupBevacizumab-First Group
15 or more letters95
10 or more letters84
SecondaryVisual Acuity

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, \<20/800), with higher scores indicating better vision.

Time frame:
2 years
Reported as:
Count of units · Eyes
Visual Acuity
EyesAflibercept- Monotherapy GroupBevacizumab-First Group
20/20 or better2928
20/40 or worse9695
20/200 or worse62
SecondaryOptical Coherence Tomography Central Subfield Thickness Change From Baseline

Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score.

Time frame:
2 years
Reported as:
Mean · microns
Optical Coherence Tomography Central Subfield Thickness Change From Baseline
micronsAflibercept- Monotherapy GroupBevacizumab-First Group
Optical Coherence Tomography Central Subfield Thickness Change From Baseline-192 ± 143-198 ± 160
SecondaryOptical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema

Optical coherence tomography (OCT) central subfield thickness equivalents for measurements obtained on Spectral domain OCT machines were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively on the Cirrus OCT measurement device (Zeiss).

Time frame:
2 years
Reported as:
Count of units · Eyes
Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema
EyesAflibercept- Monotherapy GroupBevacizumab-First Group
Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema7670
SecondaryNumber of Visits
Time frame:
2 years
Reported as:
Mean · visits
Number of Visits
visitsAflibercept- Monotherapy GroupBevacizumab-First Group
Number of Visits22.0 ± 3.622.5 ± 3.4
SecondaryNumber of Injections

All study injections were counted, including aflibercept injections received among eyes in the bevacizumab first group.

Time frame:
2 years
Reported as:
Mean · injections
Number of Injections
injectionsAflibercept- Monotherapy GroupBevacizumab-First Group
Number of Injections14.6 ± 4.116.1 ± 4.1
SecondaryNumber of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
Time frame:
Baseline to 12 weeks
Reported as:
Number · Eyes
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
EyesBevacizumab-First Group
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria16
SecondaryNumber of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
Time frame:
Baseline to 24 weeks
Reported as:
Number · Eyes
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
EyesBevacizumab-First Group
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria57
SecondaryNumber of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
Time frame:
Baseline to 52 weeks
Reported as:
Number · Eyes
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
EyesBevacizumab-First Group
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria88
SecondaryNumber of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
Time frame:
Baseline to 104 weeks
Reported as:
Number · Eyes
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria
EyesBevacizumab-First Group
Number of Eyes in the Bevacizumab-first Group Meeting the Switching Criteria100

Adverse events

Collected over 2 Years. Non-serious events are listed at a 0.01% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Unilateral Aflibercept- Monotherapy Group10/116 (8.6%)61/116 (52.6%)100/116 (86.2%)
Unilateral Bevacizumab-First Group4/112 (3.6%)42/112 (37.5%)94/112 (83.9%)
Bilateral Participants3/42 (7.1%)18/42 (42.9%)40/42 (95.2%)
Most frequent serious events
Showing 10 of 144
Most frequent serious events
EventUnilateral Aflibercept- Monotherapy GroupUnilateral Bevacizumab-First GroupBilateral Participants
Congestive heart failureCardiac disorders9/1161/1124/42
AnemiaBlood and lymphatic system disorders1/1160/1123/42
Kidney failureRenal and urinary disorders1/1167/1122/42
PneumoniaRespiratory, thoracic and mediastinal disorders6/1162/1120/42
Renal failureRenal and urinary disorders0/1160/1122/42
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/1160/1122/42
StrokeVascular disorders3/1161/1122/42
Chest painGeneral disorders5/1162/1120/42
Myocardial infarctionCardiac disorders4/1163/1120/42
DeathGeneral disorders4/1160/1121/42
Most frequent other events
Showing 10 of 419
Most frequent other events
EventUnilateral Aflibercept- Monotherapy GroupUnilateral Bevacizumab-First GroupBilateral Participants
Subconjunctival hemorrhageEye disorders9/11610/1127/42
Vitreous hemorrhageEye disorders3/1164/1127/42
Hypertension worsenedVascular disorders9/1163/1127/42
CataractEye disorders19/1167/1126/42
ColdRespiratory, thoracic and mediastinal disorders14/1168/1123/42
Posterior subcapsular cataractEye disorders11/1163/1125/42
HypertensionVascular disorders8/1165/1125/42
FloatersEye disorders10/1169/1124/42
Superficial punctate keratitisEye disorders1/1165/1124/42
CoughRespiratory, thoracic and mediastinal disorders5/1163/1124/42

Baseline characteristics

Units in Eyes

Age, Customized
Age, Customized(years)Aflibercept- Monotherapy GroupBevacizumab-First GroupTotal
age60 (55 to 66)61 (54 to 67)61 (54 to 66)
Sex/Gender, Customized
Sex/Gender, Customized(Eyes)Aflibercept- Monotherapy GroupBevacizumab-First GroupTotal
Female7674150
Male8280162
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Eyes)Aflibercept- Monotherapy GroupBevacizumab-First GroupTotal
White8283165
Black or African American322658
Hispanic or Latino394180
Asian224
Native Hawaiian or other Pacific Islander112
Multiple112
Unknown or not reported101
Type of diabetes
Type of diabetes(Eyes)Aflibercept- Monotherapy GroupBevacizumab-First GroupTotal
Type 17815
Type 2151146297
Duration of diabetes
Duration of diabetes(years)Aflibercept- Monotherapy GroupBevacizumab-First GroupTotal
Median15 (9 to 21)14 (5 to 21)15 (7 to 21)
Glycated hemoglobin
Glycated hemoglobin(Hemoglobin A1c percentage)Aflibercept- Monotherapy GroupBevacizumab-First GroupTotal
Median8.0 (7.2 to 9.4)8.0 (6.8 to 9.4)8.0 (6.9 to 9.4)
Visual acuity letter score
Visual acuity letter score(units on a scale)Aflibercept- Monotherapy GroupBevacizumab-First GroupTotal
Median61 (54 to 65)60 (51 to 65)60 (52 to 65)
Central subfield thickness
Central subfield thickness(Microns)Aflibercept- Monotherapy GroupBevacizumab-First GroupTotal
Median478 (401 to 579)496 (407 to 628)488 (404 to 616)

2 further baseline measures are reported on the registry.

08

Study locations

54 sites
  • Retinal Diagnostic Center
    Campbell, California 95008, United States
  • Macula & Retina Institute
    Glendale, California 91203, United States
  • Loma Linda University Health Care, Department of Ophthalmology
    Loma Linda, California 92354, United States
  • East Bay Retina Consultants, Inc
    Oakland, California 94609-3028, United States
  • National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
  • Florida Retina Institute-Jacksonville
    Jacksonville, Florida 32216, United States
  • Florida Retina Consultants
    Lakeland, Florida 33805, United States
  • Retina Macula Specialists of Miami
    Miami, Florida 33126, United States
  • Central Florida Retina
    Orlando, Florida 32806, United States
  • Florida Retina Institute
    Orlando, Florida 32806, United States
  • Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
    Pinellas Park, Florida 33782, United States
  • Fort Lauderdale Eye Institute
    Plantation, Florida 33324, United States
  • Retina Associates of Sarasota
    Sarasota, Florida 34233, United States
  • Sarasota Retina Institute
    Sarasota, Florida 34239, United States
  • Retina Associates of Florida, LLC
    Tampa, Florida 33609, United States
  • Retina Specialists of Tampa
    Wesley Chapel, Florida 33544, United States
  • Southeast Retina Center, P.C.
    Augusta, Georgia 30909, United States
  • Thomas Eye Group
    Sandy Springs, Georgia 30328, United States
  • Illinois Retina Associates, S.C.
    Oak Park, Illinois 60304, United States
  • Springfield Clinic, LLP
    Springfield, Illinois 62703, United States
  • Raj K. Maturi, M.D., P.C.
    Indianapolis, Indiana 46290, United States
  • John-Kenyon American Eye Institute
    New Albany, Indiana 47150, United States
  • Mid-America Retina Consultants, P.A.
    Overland Park, Kansas 66211, United States
  • Retina Associates, P.A.
    Shawnee Mission, Kansas 66204, United States
  • Paducah Retinal Center
    Paducah, Kentucky 42001, United States
  • Eye Associates of Northeast Louisiana dba Haik Humble Eye Center
    West Monroe, Louisiana 71291, United States
  • Mid Atlantic Retina Specialists
    Hagerstown, Maryland 21740, United States
  • Valley Eye Physicians and Surgeons
    Ayer, Massachusetts 01432, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • Retina Specialists of Michigan
    Grand Rapids, Michigan 49546, United States
  • Vitreo-Retinal Associates
    Grand Rapids, Michigan 49546, United States
  • The Retina Institute
    St Louis, Missouri 63128, United States
  • Eye Associates of New Mexico
    Albuquerque, New Mexico 87109, United States
  • MaculaCare
    New York, New York 10021, United States
  • Retina Associates of Western New York
    Rochester, New York 14620, United States
  • Western Carolina Clinical Research, LLC
    Asheville, North Carolina 28803, United States
  • Charlotte Eye, Ear, Nose and Throat Assoc., PA
    Charlotte, North Carolina 28210, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Dean A. McGee Eye Institute
    Oklahoma City, Oklahoma 73104, United States
  • Retina Northwest, PC
    Portland, Oregon 97221, United States
  • Cascade Medical Research Institute, LLC
    Springfield, Oregon 97477, United States
  • Retina Vitreous Consultants
    Monroeville, Pennsylvania 15146, United States
  • Retinavitreous Associates, dba; Mid Atlantic Retina
    Philadelphia, Pennsylvania 19107-5109, United States
  • Southeastern Retina Associates, P.C.
    Knoxville, Tennessee 37909, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Retina Research Center
    Austin, Texas 78705, United States
  • Retina Center of Texas
    Grapevine, Texas 76051, United States
  • Baylor Eye Physicians and Surgeons
    Houston, Texas 77030, United States
  • Retina Consultants of Houston, PA
    Houston, Texas 77030, United States
  • Texas Retina Associates
    Lubbock, Texas 79424, United States
  • Valley Retina Institute
    McAllen, Texas 78503, United States
  • Retinal Consultants of San Antonio
    San Antonio, Texas 78240, United States
  • Spokane Eye Clinic
    Spokane, Washington 99204, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network. Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14. PubMed 35833805 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Dec 2021, 48 months.

Results were first posted in Apr 2024, 2 years 4 months after primary completion.

Of 65 phase 3 interventional studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 38. This study's 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2017
First posted
Oct 25, 2017
StartActual
Dec 7, 2017
Primary completionActual
Dec 22, 2021
CompletionActual
Dec 22, 2021
Results first posted
Apr 25, 2024
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 1, 2026
Sites
1 site added, 1 site removed
Show site
  • The Retina Institute · St Louis, United States
Show 1 removed
  • The Retina Institute · Saint Louis, United States
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Posted results revised
    1 site added, 1 site removed
    Show site
    • The Retina Institute · St Louis, United States
    Show 1 removed
    • The Retina Institute · Saint Louis, United States
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03321513
Responsible party
Sponsor
First posted
Oct 25, 2017
Start date
Dec 7, 2017
Primary completion
Dec 22, 2021
Completion
Dec 22, 2021
Results posted
Apr 25, 2024
Last update
Oct 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion